Numeric Investors LLC Buys Shares of 168,290 Immune Design Corp. (IMDZ)
Numeric Investors LLC bought a new position in Immune Design Corp. (NASDAQ:IMDZ) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 168,290 shares of the biotechnology company’s stock, valued at approximately $1,641,000. Numeric Investors LLC owned approximately 0.66% of Immune Design Corp. as of its most recent SEC filing.
Other hedge funds also recently added to or reduced their stakes in the company. Bank of America Corp DE lifted its position in Immune Design Corp. by 123.3% in the 1st quarter. Bank of America Corp DE now owns 15,246 shares of the biotechnology company’s stock worth $104,000 after buying an additional 8,418 shares in the last quarter. State of Wisconsin Investment Board purchased a new stake in Immune Design Corp. in the 2nd quarter worth approximately $117,000. Alliancebernstein L.P. purchased a new stake in Immune Design Corp. in the 2nd quarter worth approximately $118,000. Virtu KCG Holdings LLC purchased a new stake in Immune Design Corp. in the 2nd quarter worth approximately $153,000. Finally, Trexquant Investment LP purchased a new stake in Immune Design Corp. in the 1st quarter worth approximately $183,000. Institutional investors own 51.46% of the company’s stock.
Immune Design Corp. (IMDZ) opened at 10.50 on Monday. Immune Design Corp. has a 12-month low of $4.50 and a 12-month high of $13.05. The company’s market cap is $269.00 million. The stock’s 50 day moving average is $9.96 and its 200-day moving average is $8.40.
Immune Design Corp. (NASDAQ:IMDZ) last released its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.54) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.65) by $0.11. The company had revenue of $0.73 million during the quarter, compared to analysts’ expectations of $1.50 million. Immune Design Corp. had a negative net margin of 324.33% and a negative return on equity of 59.14%. Analysts predict that Immune Design Corp. will post ($2.34) earnings per share for the current fiscal year.
In other Immune Design Corp. news, Director Lewis W. Coleman acquired 12,000 shares of the business’s stock in a transaction dated Tuesday, July 11th. The shares were acquired at an average price of $9.05 per share, with a total value of $108,600.00. Following the completion of the transaction, the director now directly owns 40,000 shares in the company, valued at approximately $362,000. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Leo Guthart acquired 10,000 shares of the business’s stock in a transaction dated Monday, September 18th. The stock was acquired at an average cost of $9.70 per share, for a total transaction of $97,000.00. The disclosure for this purchase can be found here. 20.70% of the stock is owned by corporate insiders.
IMDZ has been the subject of a number of research analyst reports. Zacks Investment Research upgraded shares of Immune Design Corp. from a “hold” rating to a “buy” rating and set a $11.00 target price for the company in a research report on Tuesday, July 18th. ValuEngine downgraded shares of Immune Design Corp. from a “hold” rating to a “sell” rating in a research report on Monday, October 2nd. Jefferies Group LLC reiterated a “buy” rating and issued a $18.00 target price on shares of Immune Design Corp. in a research report on Wednesday, June 28th. BidaskClub downgraded shares of Immune Design Corp. from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 5th. Finally, Royal Bank Of Canada initiated coverage on shares of Immune Design Corp. in a research report on Thursday, September 14th. They issued an “outperform” rating and a $20.00 target price for the company. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $16.33.
About Immune Design Corp.
Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer.
Want to see what other hedge funds are holding IMDZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Immune Design Corp. (NASDAQ:IMDZ).
Receive News & Stock Ratings for Immune Design Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design Corp. and related stocks with our FREE daily email newsletter.